| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/03/2003 | US20030125247 A Therapeutic protein (e.g., a polypeptide, antibody, or peptide, or fragments and variants) fused to albumin, is sufficient to prolong the shelf-lilfe of therapeutic protein |
| 07/03/2003 | US20030125235 Treating a condition comprising administering a pharmaceutically effective amount of an inhibitor of the Tec family of protein tyrosine kinases (PTKs). The condition is typically associated with cytokine production, for treatment |
| 07/03/2003 | US20030124678 Interleukin-2 mutants with reduced toxicity |
| 07/03/2003 | US20030124677 Amino-terminally truncated MCP-2 as chemokine antagonists |
| 07/03/2003 | US20030124655 Receptor protein specifically recognizing bacterial dna |
| 07/03/2003 | US20030124649 Membrane associated proteins |
| 07/03/2003 | US20030124602 Tumour suppresor and uses thereof |
| 07/03/2003 | US20030124593 Methods and compositions for the treatment and diagnosis of cellular proliferation disorders using 25943 |
| 07/03/2003 | US20030124582 Polypeptide encoded by a polynucleotide of given sequence; detecting the effect of a test compound on the production of mRNA; use in identifying agonists/antagonists that may be useful in therapy |
| 07/03/2003 | US20030124557 Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function |
| 07/03/2003 | US20030124540 Interventions to mimic the effects of calorie restriction |
| 07/03/2003 | US20030124534 Measuring expression of nucleotide sequences in cells |
| 07/03/2003 | US20030124529 Pregnancy-associated plasma protein-A2 (PAPP-A2) |
| 07/03/2003 | US20030124196 Pulsatile release compositions and methods for enhanced intestinal drug absorption |
| 07/03/2003 | US20030124193 Atomizing nozzles include a liquid nozzle adapted to disperse a supply of liquid and a gas nozzle adapted to disperse a supply of gas; spray drying at a commercial plant scale. |
| 07/03/2003 | US20030124150 Kit for reducing aching |
| 07/03/2003 | US20030124142 Immunomodulatory constructs and their uses |
| 07/03/2003 | US20030124136 Immunotherapy for reversing immune suppression |
| 07/03/2003 | US20030124132 Using targeted or non-targeted coagulants to cause tumor vasculature thrombosis. |
| 07/03/2003 | US20030124129 Angiopoietin-2 specific binding agents |
| 07/03/2003 | US20030124116 Antibodies binding to polypeptides encoded by the genes |
| 07/03/2003 | US20030124114 Genes that encode cell surface molecules with conserved IgV and mucin domains; diagnosis or staging of cancer; treatment of an immunological disorder; detecting a predisposition to asthma |
| 07/03/2003 | US20030124107 PAK5-related compositions and methods |
| 07/03/2003 | US20030124105 Programmed cell death genes and proteins |
| 07/03/2003 | US20030124100 Includes an endothelial specific enhancer element; especially modifications of the PPE promoter, which enhance its expression in response to hypoxia and angiogenesis. |
| 07/03/2003 | US20030124058 Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| 07/03/2003 | US20030124057 Complex of antibody and radionucleotide; therapy, medical diagnosis |
| 07/03/2003 | US20030124056 Carrier molecules |
| 07/03/2003 | US20030124054 Antitumor agents; anticancer agents; viricides |
| 07/03/2003 | CA2471461A1 Pyrrolidine-2-ones as factor xa inhibitors |
| 07/03/2003 | CA2471396A1 Ultrapure oral fludara formulation with a fast releasing active substance |
| 07/03/2003 | CA2471140A1 Antibodies that immunospecifically bind to trail receptors |
| 07/03/2003 | CA2471110A1 Peptides for treatment of the human papillomavirus(hpv)-associated cancer and other epithelial tumors |
| 07/03/2003 | CA2471107A1 Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators |
| 07/03/2003 | CA2471085A1 Aroyl pyridinones |
| 07/03/2003 | CA2471083A1 Benzhydryl derivatives |
| 07/03/2003 | CA2471079A1 Piperidine-2,6-diones heterocyclically substituted in the 3-position |
| 07/03/2003 | CA2470999A1 Syn3 compositions and methods |
| 07/03/2003 | CA2470976A1 Ph-sensitive polymeric conjugates of an anthracycline drug |
| 07/03/2003 | CA2470938A1 Treatment of ebv and khsv infection and associated abnormal cellular proliferation |
| 07/03/2003 | CA2470900A1 Compositions and methods for the diagnosis and treatment of tumor |
| 07/03/2003 | CA2470844A1 Novel compositions and methods for cancer |
| 07/03/2003 | CA2470594A1 Leptin proteins |
| 07/03/2003 | CA2470576A1 Methods for slowing senescence and treating and preventing diseases associated with senescence |
| 07/03/2003 | CA2470316A1 Lyophilized preparation containing antibodies to the egf receptor |
| 07/03/2003 | CA2470178A1 Mammalian simp protein, gene sequence and uses thereof in cancer therapy |
| 07/03/2003 | CA2469263A1 Raf/ras binding compounds |
| 07/03/2003 | CA2469047A1 Tempamine compositions and methods of use |
| 07/03/2003 | CA2468882A1 A library of modified structural genes or capsid modified particles useful for the identification of viral clones with desired cell tropism |
| 07/03/2003 | CA2468627A1 Liposome composition for delivery of nucleic acid |
| 07/03/2003 | CA2466483A1 Diagnosis prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling |
| 07/03/2003 | CA2451993A1 Polypeptide, its conjugate with doxorubicin and conjugate-based pharmaceutical composition |
| 07/02/2003 | EP1323824A2 Use of human keratinocyte growth factor-2 for the preparation of pharmaceutical compositions |
| 07/02/2003 | EP1323735A1 Gene relating to drug tolerance and utilization thereof |
| 07/02/2003 | EP1323714A1 1,3-selenazole derivatives and their use as anticancer drugs or as agrochemicals |
| 07/02/2003 | EP1323423A1 Combined preparations comprising anthracycline derivatives |
| 07/02/2003 | EP1322778A2 Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas |
| 07/02/2003 | EP1322769A2 Protein phosphatases |
| 07/02/2003 | EP1322768A2 Isolation of drosophila and human polynucleotides encoding par-1 kinase, polypeptides encoded by the polynucleotides and methods utilizing the polynucleotides and polypeptides |
| 07/02/2003 | EP1322760A2 G-protein coupled receptors |
| 07/02/2003 | EP1322755A1 Human and mouse targeting peptides identified by phage display |
| 07/02/2003 | EP1322752A2 Fad4, fad5, fad5-2, and fad6, fatty acid desaturase family members and uses thereof |
| 07/02/2003 | EP1322673A1 Polysaccharides with antithrombotic activity comprising at least a covalent bond with biotin or a biotin derivative |
| 07/02/2003 | EP1322668A2 A novel human g-protein coupled receptor, hgprbmy7, expressed highly in spinal cord |
| 07/02/2003 | EP1322660A2 17alpha-fluoroalkyl steroids, method for producing the same and pharmaceutical compositions containing said compounds |
| 07/02/2003 | EP1322656A2 Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| 07/02/2003 | EP1322654A1 Platinum complexes as antitumor agents |
| 07/02/2003 | EP1322653A2 Metal complexes for use in medical and therapeutic applications |
| 07/02/2003 | EP1322652A1 Stereoselective process for preparing cyclohexyl amine derivatives |
| 07/02/2003 | EP1322650A2 Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives |
| 07/02/2003 | EP1322646A1 2-(1h-indol-3-yl)-2-oxo-acetic acid amides with antitumor activity |
| 07/02/2003 | EP1322645A2 Quinazolines, medicaments, which contain these compounds and which are effective as tyrosine kinase inhibitors, their use, and methods for the production thereof |
| 07/02/2003 | EP1322644A1 Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives |
| 07/02/2003 | EP1322642A2 sHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES BEARING BOTH LIPOPHILIC AND IONISABLE MOIETIES AS INHIBITORS OF PROTEIN JUNKINASES |
| 07/02/2003 | EP1322641A1 Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein junkinases |
| 07/02/2003 | EP1322636A1 Farnesyl transferase inhibiting 6- (substituted phenyl)methyl]-quinoline and quinazoline derivatives |
| 07/02/2003 | EP1322635A1 Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors |
| 07/02/2003 | EP1322634A1 N-phenyl-2-pyrimidine-amine derivatives |
| 07/02/2003 | EP1322631A2 Methods of providing and using compounds ( retinoids ) having activity as inhibitors of cytochrome p450rai |
| 07/02/2003 | EP1322628A2 Substituted urea neuropeptide y y5 receptor antagonists |
| 07/02/2003 | EP1322623A2 Hydroxy acid integrin antagonists |
| 07/02/2003 | EP1322617A1 Compounds and methods for modulation of estrogen receptors |
| 07/02/2003 | EP1322615A2 Fluorinated quinolones as antimitotic and antitumor agents |
| 07/02/2003 | EP1322383A2 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
| 07/02/2003 | EP1322350A1 E-ptfe foil impregnated with an encapsulated bioactive substance |
| 07/02/2003 | EP1322338A2 Compositions and methods of using capsid protein from flaviviruses and pestiviruses |
| 07/02/2003 | EP1322336A1 Method of increasing testosterone and related steroid concentrations in women |
| 07/02/2003 | EP1322334A2 Methods of inducing cancer cell death and tumor regression |
| 07/02/2003 | EP1322333A2 Composition for combined use of aromatase inhibitors |
| 07/02/2003 | EP1322323A1 Thionin as an antineoplastic and immunostimulant |
| 07/02/2003 | EP1322321A2 Use of lipopeptides or lipoproteins for treating lung infections and lung tumours |
| 07/02/2003 | EP1322317A1 Compositions and methods for prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with compositions comprising unfractionated cellular proteins |
| 07/02/2003 | EP1322315A1 Formulations for reducing or eliminating toxicity of environmental hormones containing ursodeoxycholic acid |
| 07/02/2003 | EP1322310A1 Alpha v integrin receptor antagonists |
| 07/02/2003 | EP1322307A1 Methods for treating cell proliferative disorders and viral infections |
| 07/02/2003 | EP1322304A1 Manipulation of oxidative phosphorylation for hypersensitizing tumor cells to glycolytic inhibitors |
| 07/02/2003 | EP1322302A2 Taxoid conjugates as antimitotic and antitumor agents |
| 07/02/2003 | EP1322300A1 Inhalation particles incorporating a combination of two or more active ingredients |
| 07/02/2003 | EP1322286A2 Polymeric delivery formulations of leuprolide with improved efficacy |
| 07/02/2003 | EP1239885A4 Interventions to mimic the effects of calorie restriction |